-
Your selected country is
Norway
- Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).
Product Notices
- This antibody was developed for use in flow cytometry.
- The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
- Researchers should determine the optimal concentration of this reagent for their individual applications.
- An isotype control should be used at the same concentration as the antibody of interest.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
- BD Horizon Brilliant Violet 650 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,455,613; 8,575,303; 8,354,239.
- Alexa Fluor® is a registered trademark of Life Technologies Corporation.
Companion Products
The 1A29 monoclonal antibody specifically recognizes ICAM-1 which is also known as CD54. ICAM-1 is an 85 kDa type I transmembrane glycoprotein that is encoded by Icam1 (Intercellular adhesion molecule 1). It is expressed on vascular endothelium in lymphoid tissues, thymic stromal cells, peripheral blood monocytes, peritoneal macrophages and mast cells, dendritic cells, and weakly on peripheral lymphocytes and thymocytes. ICAM-1 is a ligand for LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18). Its expression is upregulated on activated lymphocytes and endothelial cells. 1A29 mAb inhibits Phorbol 12-Myristate 13-Acetate (PMA)-induced aggregation of phytohemagglutinin (PHA)-stimulated splenic blasts, as well as the adhesion of mitogen-stimulated blasts to high endothelial venule (HEV) cells and purified ICAM-1. The 1A29 antibody can reportedly inhibit leucocyte infiltration in in vivo systems, blocks induction of experimental allergic encephalomyelitis, and reduces NK-cell adhesion to tumor cells.
The antibody was conjugated to BD Horizon™ BV650 which is part of the BD Horizon Brilliant™ Violet family of dyes. This dye is a tandem fluorochrome of BD Horizon BV421 with an Ex Max of 405-nm and an acceptor dye with an Em Max at 650-nm. BD Horizon BV650 can be excited by the violet laser and detected in a filter used to detect APC-like dyes (eg, 660/20-nm filter). Due to the excitation and emission characteristics of the acceptor dye, there will be spillover into the APC and Alexa Fluor® 700 detectors. However, the spillover can be corrected through compensation as with any other dye combination.
Development References (16)
-
Andrews FJ, Malcontenti-Wilson C, O'Brien PE. Expression of adhesion molecules and leukocyte recruitment into gastric mucosa following ischemia-reperfusion. Dig Dis Sci. 1997; 42(2):326-332. (Biology). View Reference
-
Bañuls MP, Alvarez A, Ferrero I, Zapata A, Ardavin C. Cell-surface marker analysis of rat thymic dendritic cells. Immunology. 1993; 79(2):298-304. (Clone-specific). View Reference
-
Chen-Woan M, Delaney CP, Fournier V, et al. In vitro characterization of rat bone marrow-derived dendritic cells and their precursors. J Leukoc Biol. 1996; 59(2):196-207. (Clone-specific). View Reference
-
Divya Jyothi M, Varalakshmi C, Khar A. Regulation of effector cell functions through the ligation of lymphocyte function-associated antigen-1 and intracellular adhesion molecule-1 leads to spontaneous regression of a rat histiocytoma. Scand J Immunol. 1999; 50(4):378-386. (Clone-specific: Blocking, In vivo exacerbation). View Reference
-
Fox CC, Jewell SD, Whitacre CC. Rat peritoneal mast cells present antigen to a PPD-specific T cell line. Cell Immunol. 1994; 158(1):253-264. (Clone-specific). View Reference
-
Liu L, Zhang M, Jenkins C, MacPherson GG. Dendritic cell heterogeneity in vivo: two functionally different dendritic cell populations in rat intestinal lymph can be distinguished by CD4 expression. J Immunol. 1998; 161(3):1146-1155. (Clone-specific). View Reference
-
Machelska H, Mousa SA, Brack A, et al. Opioid control of inflammatory pain regulated by intercellular adhesion molecule-1. J Neurosci. 2002; 22(13):5588-5596. (Biology). View Reference
-
Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 1994; 76(2):301-314. (Biology). View Reference
-
Tamatani T, Kotani M, Miyasaka M. Characterization of the rat leukocyte integrin, CD11/CD18, by the use of LFA-1 subunit-specific monoclonal antibodies. Eur J Immunol. 1991; 21(3):627-633. (Clone-specific: Inhibition). View Reference
-
Tamatani T, Miyasaka M. Identification of monoclonal antibodies reactive with the rat homolog of ICAM-1, and evidence for a differential involvement of ICAM-1 in the adherence of resting versus activated lymphocytes to high endothelial cells. Int Immunol. 1990; 2(2):165-171. (Immunogen: Inhibition). View Reference
-
Turunen JP, Ustinov J, Renkonen R. Adhesion molecules involved in protein kinase A- and C-dependent lymphocyte adherence to microvascular endothelial cells. Scand J Immunol. 1993; 37(3):282-288. (Biology). View Reference
-
Watanabe T, Arakawa T, Fukuda T, Higuchi K, Kobayashi K. Role of neutrophils in a rat model of gastric ulcer recurrence caused by interleukin-1 beta. Am J Pathol. 1997; 150(3):971-979. (Biology). View Reference
-
Westermann J, Nagahori Y, Walter S, Heerwagen C, Miyasaka M, Pabst R. B and T lymphocyte subsets enter peripheral lymph nodes and Peyer's patches without preference in vivo: no correlation occurs between their localization in different types of high endothelial venules and the expression of CD44, VLA-4, LFA-1, ICAM-1, CD2 or L-selectin. Eur J Immunol. 1994; 24(10):2312-2316. (Clone-specific). View Reference
-
Willenborg DO, Staykova MA, Miyasaka M. Short term treatment with soluble neuroantigen and anti-CD11a (LFA-1) protects rats against autoimmune encephalomyelitis: treatment abrogates autoimmune disease but not autoimmunity. J Immunol. 1996; 157(5):1973-1980. (Clone-specific: Blocking). View Reference
-
Xia WJ, Schneeberger EE, McCarthy K, Kradin RL. Accessory cells of the lung. II. Ia+ pulmonary dendritic cells display cell surface antigen heterogeneity. Am J Respir Cell Mol Biol. 1991; 5(3):276-283. (Clone-specific). View Reference
-
Yamazaki T, Seko Y, Tamatani T, et al. Expression of intercellular adhesion molecule-1 in rat heart with ischemia/reperfusion and limitation of infarct size by treatment with antibodies against cell adhesion molecules. Am J Pathol. 1993; 143(2):410-418. (Clone-specific: Inhibition). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.